Proteome Sciences plc (LON:PRM – Get Free Report)’s stock price traded down 5.1% during mid-day trading on Friday . The stock traded as low as GBX 1.50 and last traded at GBX 1.67. 538,226 shares traded hands during mid-day trading, an increase of 117% from the average session volume of 248,370 shares. The stock had previously closed at GBX 1.76.
Proteome Sciences Trading Up 0.1%
The business has a 50 day moving average of GBX 2.40 and a 200 day moving average of GBX 2.84. The firm has a market capitalization of £5.20 million, a price-to-earnings ratio of -1.56 and a beta of 0.07. The company has a debt-to-equity ratio of -258.66, a current ratio of 0.20 and a quick ratio of 0.37.
Proteome Sciences (LON:PRM – Get Free Report) last released its earnings results on Thursday, September 25th. The company reported GBX (0.73) earnings per share for the quarter. Proteome Sciences had a negative net margin of 0.04% and a negative return on equity of 0.01%.
About Proteome Sciences
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant, provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator, analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids.
See Also
- Five stocks we like better than Proteome Sciences
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Rivian’s Chart Says Go, But Some Analysts Still Say No
- Dividend Payout Ratio Calculator
- e.l.f. Sell-Off Is a Good Time to Buy, According to Analysts
- Growth Investing: Should You Adopt This Investing Strategy in 2022?
- T-Mobile Is The Most Oversold Mega-Cap Stock—Time to Buy?
Receive News & Ratings for Proteome Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteome Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
